Urinary and genital infections in patients with diabetes: How to diagnose and how to treat

Diabetes and Metabolism

Volumn 42, Issue 1, 2016, Pages 16-24

  Njomnang Soh, P ^a   Vidal, F ^b   Huyghe, E ^c   Gourdy, P ^c   Halimi, J M ^d   Bouhanick, B ^c  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU PURPAN   (France)

^c CHU RANGUEIL   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Diabetes; Genital infections; Review; SGLT2 inhibitors; Urinary infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BORIC ACID; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; FOSFOMYCIN TROMETAMOL; ITRACONAZOLE; KANAMYCIN; METRONIDAZOLE; MICONAZOLE; NITROFURANTOIN; PENICILLIN DERIVATIVE; PIVMECILLINAM; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SECNIDAZOLE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TINIDAZOLE;

BALANITIS; CYSTITIS; DIABETES MELLITUS; EPIDIDYMITIS; FEMALE; GENITAL TRACT INFECTION; HIGH RISK POPULATION; HUMAN; MALE; ORCHITIS; PROSTATITIS; REVIEW; SEMEN ANALYSIS; TRICHOMONAS VAGINALIS; URETHRITIS; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS; VULVOVAGINITIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; REPRODUCTIVE TRACT INFECTIONS; URINARY TRACT INFECTIONS;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; REPRODUCTIVE TRACT INFECTIONS; URINARY TRACT INFECTIONS;

EID: 84940056292     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.07.002     Document Type: Review

References (58)

1. Benfield T., Jensen J.S., Nordestgaard B.G. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007, 50:549-554.
2. de Leon E.M., Jacober S.J., Sobel J.D., Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002, 2:1.
3. Andriole V.T. Asymptomatic bacteriuria in patients with diabetes - enemy or innocent visitor?. N Engl J Med 2002, 347:1617-1618.
4. Hirji I., Andersson S.W., Guo Z., Hammar N., Gomez-Caminero A. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012, 26:501-505.
5. Varkarakis J., Sebe P., Pinggera G.M., Bartsch G., Strasser H. Three-dimensional ultrasound guidance for percutaneous drainage of prostatic abscesses. Urology 2004, 63:1017-1020. [discussion 1020].
6. Beigi R.H., Meyn L.A., Moore D.M., Krohn M.A., Hillier S.L. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004, 104:926-930.
7. French Society for Infectious Disease (SPILF) Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires de l'adulte 2014, [Available from: http://www.infectiologie.com/site/medias/Recos/2014-infections_urinaires-court.pdf].
8. Andrade-Rocha F.T. Editorial Comment to Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis. Int J Urol 2015, 22:512-513.
9. Busolo F., Camposampiero D., Bordignon G., Bertollo G. Detection of Mycoplasma genitalium and Chlamydia trachomatis DNAs in male patients with urethritis using the polymerase chain reaction. New Microbiol 1997, 20:325-332.
10. Wetmore C.M., Manhart L.E., Lowens M.S., Golden M.R., Whittington W.L., Xet-Mull A.M., et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis 2011, 38:180-186.
11. Prevention CfDCa Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae - 2014. MMWR Recomm Rep 2014, 63:1-19.
12. Collins M.M., Meigs J.B., Barry M.J., Walker Corkery E., Giovannucci E., Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002, 167:1363-1366.
13. Roberts R.O., Lieber M.M., Rhodes T., Girman C.J., Bostwick D.G., Jacobsen S.J. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998, 51:578-584.
14. Wagenlehner F.M., Weidner W., Sorgel F., Naber K.G. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005, 26:1-7.
15. Engeler D., Baranowski A.P., Elneil S., Hughes J. EAU Guidelines on chronic pelvic pain 2012, European Association of Urology.
16. Krieger J.N., Nyberg L., Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 1999, 282:236-237.
17. Meares E.M., Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968, 5:492-518.
18. McNaughton Collins M., Fowler F.J., Elliott D.B., Albertsen P.C., Barry M.J. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?. Urology 2000, 55:403-407.
19. Budia A., Luis Palmero J., Broseta E., Tejadillos S., Benedicto A., Queipo J.A., et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol 2006, 40:326-331.
20. Naber K.G., Sorgel F. Antibiotic therapy - rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003, 35:331-335.
21. Naber K.G., Weidner W. Prostatitis, epididymitis and orchitis. Infect Dis 1999.
22. Rowe P., Comhaire F., Hargreave T., Mellows H. WHO manual for the standardized investigation and diagnosis of the infertile couple 1993, 1993. Press Syndicate of the University of Cambridge, Cambridge.
23. Microbiology FSo Rémic : référentiel en microbiologie médicale 2010.
24. Vicari E. Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection. Hum Reprod 2000, 15:2536-2544.
25. Vicari E., La Vignera S., Calogero A.E. Antioxidant treatment with carnitines is effective in infertile patients with prostatovesiculoepididymitis and elevated seminal leukocyte concentrations after treatment with nonsteroidal anti-inflammatory compounds. Fertil Steril 2002, 78:1203-1208.
26. Agarwal A., Saleh R.A., Bedaiwy M.A. Role of reactive oxygen species in the pathophysiology of human reproduction. Fertil Steril 2003, 79:829-843.
27. Sanocka D., Jedrzejczak P., Szumala-Kaekol A., Fraczek M., Kurpisz M. Male genital tract inflammation: the role of selected interleukins in regulation of pro-oxidant and antioxidant enzymatic substances in seminal plasma. J Androl 2003, 24:448-455.
28. Gupta K., Trautner B.W. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ 2013, 346:f3140.
29. Hooton T.M. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012, 366:1028-1037.
30. Donders G.G., Babula O., Bellen G., Linhares I.M., Witkin S.S. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008, 115:1225-1231.
31. Achkar J.M., Fries B.C. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010, 23:253-273.
32. Geerlings S., Fonseca V., Castro-Diaz D., List J., Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014, 103:373-381.
33. Goswami R., Dadhwal V., Tejaswi S., Datta K., Paul A., Haricharan R.N., et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 2000, 41:162-166.
34. Mylonas I., Bergauer F. Diagnosis of vaginal discharge by wet mount microscopy: a simple and underrated method. Obstet Gynecol Surv 2011, 66:359-368.
35. Mendling W. Guideline: vulvovaginal candidosis (AWMF 015/072). S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015, 58(Suppl 1):1-15.
36. Workowski K.A., Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59:1-110.
37. Sobel J.D. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Prefer Adherence 2013, 8:31-34.
38. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
39. Phillips A.J. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005, 192:2009-2012. [discussion 2012-3].
40. Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351:876-883.
41. Iavazzo C., Gkegkes I.D., Zarkada I.M., Falagas M.E. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt) 2011, 20:1245-1255.
42. Pirotta M., Gunn J., Chondros P., Grover S., O'Malley P., Hurley S., et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004, 329:548.
43. Falagas M.E., Betsi G.I., Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006, 58:266-272.
44. Goswami D., Goswami R., Banerjee U., Dadhwal V., Miglani S., Lattif A.A., et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect 2006, 52:111-117.
45. Donders G.G., Zodzika J., Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother 2014, 15:645-657.
46. Schwebke J.R., Muzny C.A., Josey W.E. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis 2014, 210:338-343.
47. Sharma H., Tal R., Clark N.A., Segars J.H. Microbiota and pelvic inflammatory disease. Semin Reprod Med 2014, 32:43-49.
48. Bradshaw C.S., Morton A.N., Hocking J., Garland S.M., Morris M.B., Moss L.M., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006, 193:1478-1486.
49. Sobel J.D. Bacterial vaginosis. Annu Rev Med 2000, 51:349-356.
50. Cruciani F., Brigidi P., Calanni F., Lauro V., Tacchi R., Donders G., et al. Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota. Antimicrob Agents Chemother 2012, 56:4062-4070.
51. Mastromarino P., Vitali B., Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol 2013, 36:229-238.
52. Bradshaw C.S., Pirotta M., De Guingand D., Hocking J.S., Morton A.N., Garland S.M., et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One 2012, 7:e34540.
53. Coleman J.S., Gaydos C.A., Witter F. Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstet Gynecol Surv 2013, 68:43-50.
54. Schwebke J.R., Hobbs M.M., Taylor S.N., Sena A.C., Catania M.G., Weinbaum B.S., et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011, 49:4106-4111.
55. Forna F., Gulmezoglu A.M. Interventions for treating trichomoniasis in women. Cochrane Database Syst Revs 2003, (2):CD000218.
56. Tansarli G.S., Kostaras E.K., Athanasiou S., Falagas M.E. Prevalence and treatment of aerobic vaginitis among non-pregnant women: evaluation of the evidence for an underestimated clinical entity. Eur J Clin Microbiol Infect Dis 2013, 32:977-984.
57. Tempera G., Furneri P.M. Management of aerobic vaginitis. Gynecol Obstet Invest 2010, 70:244-249.
58. Donders G.G., Van Bulck B., Van de Walle P., Kaiser R.R., Pohlig G., Gonser S., et al. Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor(R)) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest 2010, 70:264-272.